A2 BIOTHERAPEUTICS RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR A2B543, A LOGIC-GATED CAR T-CELL THERAPY ENHANCED WITH A MEMBRANE-TETHERED IL-12 BOOSTER
Further company coverage: [ ]
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.